Art Weber’s 5-year-old, Whitney, has a serious allergy to bee stings, so he and his wife are among the many people who shell out roughly $600 annually for a two-pack of EpiPens.
Whitney, however, isn’t a little girl. She’s a beagle that could go into shock without a prompt dose of life-saving epinephrine.
Soaring prices for prescription drugs aren’t just a problem for human patients.Read more
Wells Fargo may have gone out if its way to take senior citizens to the cleaners when the bank’s workers fraudulently opened as many as 2 million accounts without customers’ permission.
At least that’s the suspicion of Democratic Sen. Claire McCaskill of Missouri and Republican Sen. Susan Collins of Maine, the top members of the Senate Special Committee on Aging.Read more
Heather Bresch, chief executive of pharmaceutical heavyweight Mylan, testified before lawmakers Wednesday that her company acted ethically and fairly when it jacked up the price of life-saving EpiPens by more than 500%.Read more
Healthcare is very much in the news, but for all the wrong reasons.
On the one hand, we had Republican presidential nominee Donald Trump visiting the “Dr. Oz” show last week to reveal some tidbits about his physical condition (he’s fat). On the other, Democratic nominee Hillary Clinton had a bout of pneumonia but declared herself fit as a fiddle (we’ll see).Read more
Welcome to California Inc., the weekly newsletter of the L.A. Times Business Section.
I'm Business columnist David Lazarus, and here's a rundown of upcoming stories this week and the highlights of last week.
Some good news on the home front: California employers quieted any lingering doubts about the state’s economy in August.Read more